Analyst Price Target is $25.00
▲ +412.30% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for BriaCell Therapeutics in the last 3 months. The average price target is $25.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 412.30% upside from the last price of $4.88.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in BriaCell Therapeutics.
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.